Treatment for CD20-positive central nervus system lymphoma with autologous serum and rituximab into the ventricle
Not Applicable
- Conditions
- CD20-positive primary central nervus system lymphoma, or relapsed CD20-positive non-Hodgkin lymphoma in CNS alone
- Registration Number
- JPRN-UMIN000000968
- Lead Sponsor
- Division of Hematology, University of Tsukuba
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 5
Inclusion Criteria
Not provided
Exclusion Criteria
Poor general status (ECOG Performance status 3 or 4). Inablity in understanding of the therapy even due to the primary disease. Lesions outside of central nervas system which are uncontroled or less than three months from shrinking.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response
- Secondary Outcome Measures
Name Time Method